Acadia Pharmaceuticals Inc. · NASDAQ:ACAD
Acadia Pharmaceuticals — Technical Presentation (September 2026)
19 slides from Acadia Pharmaceuticals's technical presentation, Sep 24, 2026
Slide 1: RADIANT Phase 2 Topline Results Conference Call
SEPTEMBER 24, 2026 RADIANT Phase 2 Topline Results Conference Call Evaluating Remlifanserin for the treatment of Alzheimer’s Disease Psychosis
Slide 2: Call Agenda
Call Agenda Welcome Al Kildani | Senior Vice President, Investor Relations and Corporate Communications Opening Remarks Catherine Owen Adams | Chief Executive Officer RADIANT Phase 2 Topline Results Elizabeth H.Z. Thompson | Executive Vice President, Head of Research and Development Closing Rema
Slide 3: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements other than statements of historical fact and can be identified by terms such as “may,” “will,
Slide 4: Opening Remarks
Opening Remarks Catherine Owen Adams Chief Executive Officer
Slide 5: RADIANT: Phase 2 Remlifanserin ADP Data Are Enabling for Phase 3 Program
RADIANT: Phase 2 Remlifanserin Alzheimer’s Disease Psychosis (ADP) Data Are Enabling for Phase 3 Program Efficacy Safety & Tolerability Phase 3 Enabling Meaningful and consistent Safety and tolerability profile in Data support the continued efficacy trends across the study was favorable development
Slide 6: RADIANT Phase 2 Topline Results
RADIANT Phase 2 Topline Results Elizabeth H.Z. Thompson, Ph.D. Executive Vice President, Head of Research and Development
Slide 7: Remlifanserin: RADIANT Phase 2 Trial in ADP
Remlifanserin: RADIANT Phase 2 Trial in ADP PHASE 2 N=363, double-blind, randomized 1:1:1 PRIM ARY ENDPOINT Remlifanserin (60 mg QD) 126 Randomized → 109 mFAS SAPS-H+D total score change from baseline to Week 6 Remlifanserin (30 mg QD) 121 Randomized → 110 mFAS KEY S ECONDARY ENDPOINT CGI-S-ADP chan
Slide 8: Demographics and Baseline Disease Characteristics (mFAS)
Demographics and Baseline Disease Characteristics (mFAS) Placebo Remlifanserin 30 mg Remlifanserin 60 mg Remlifanserin Overall n (%) N=107 n (%) N=110 n (%) N=109 n (%) N=219 Sex, n (%) Female 68 (64) 69 (63) 75 (69) 144 (66) Male 39 (36) 41 (37) 34 (31) 75 (34) Age at Randomization (years) Mean (SD
Slide 9: Remlifanserin Narrowly Missed Primary Endpoint. Nominally Significant Key Secondary
Remlifanserin Narrowly Missed Primary Endpoint. Nominally Significant Key Secondary Placebo Remlifanserin 30 mg Remlifanserin 60 mg (N=107) (N=110) (N=109) Change Change Change from from Standardized from Standardized P-value P-value Baseline Baseline Effect Size Baseline Effect Size (LSM) (LSM) (LS
Slide 10: Consistent Improvement Across Primary and Key Secondary Endpoint
Consistent Improvement Across Primary and Key Secondary Endpoint with Increasing Separation Through Week 6 Primary Endpoint: SAPS-H+D Total Score Key Secondary: CGI-S-ADP Score LS Mean Change from Baseline (SE) 0 -1 -0.2 -3 -0.4 -5 -0.6 -7 -0.8 -9 -1 -11 -1.2 Placebo Placebo -13 Remlifanserin 30 mg
Slide 11: Subgroup of Modestly Higher Baseline Psychosis Improves Separation
Subgroup of Modestly Higher Baseline Psychosis (80% of Trial Population) Improves Separation Throughout Treatment Period Primary Endpoint: SAPS-H+D Total Score Key Secondary: CGI-S-ADP Score LS Mean Change from Baseline (SE) 0 -1 -0.2 -3 -0.4 -5 -0.6 ES=0.43 -7 ES=0.33 -0.8 -9 -1 -11 -1.2 -13 Placeb
Slide 12: Phase 2 Safety Profile Supports Continued Phase 3 Development
Phase 2 Safety Profile Supports Continued Phase 3 Development • No signal of QT prolongation vs placebo • Low rates of serious adverse events and discontinuations due to adverse events • No AE was seen in more than 5% of patients receiving 60 mg remlifanserin • Only somnolence (3.2%) and nausea (2.4
Slide 13: Next Steps
Next Steps • Detailed safety and efficacy results to be shared at Clinical Trials on Alzheimer's Disease (CTAD) November 16-19, 2026 in Boston • Phase 3 enrollment continues while we implement amendments to the program, including removing the 30 mg dosage arm 13
Slide 14: Closing Remarks
Closing Remarks Catherine Owen Adams Chief Executive Officer
Slide 15: ADP is Common in Alzheimer's Disease and Represents a Substantial Unmet Need
Alzheimer's Disease Psychosis (ADP) is Common in Alzheimer’s Disease and Represents a Substantial Unmet Need ADP is a condition in which a person with Alzheimer's ~7M Patients disease experiences in the U.S. with Alzheimer’s disease hallucinations or delusions There are no approved Approximately 30%
Slide 16: Overview of Lewy Body Dementia (LBD)
Overview of Lewy Body Dementia (LBD) A progressive brain disorder that affects thinking, movement, mood, and behavior that is associated >1M Patients with abnormal deposits of alpha- in the U.S. may be living with LBD4 synuclein in the brain1,2 No therapies are approved for 50%-75% of people with LB
Slide 17: Potential Growth Outlook
Potential Growth Outlook ~$11B Full Global Peak Sales Potential (Unadjusted) ACP-211 ACP-711 ACP-271 ~$1.7B Projected FY 2028 Global Net Sales Internal Acadia estimates for full potential peak sales for pipeline ~$4B molecules as of September 24, 2026, assuming all successfully Remlifanserin approve
Slide 18: Advancing a Robust Pipeline with Multiple Value-Driving Milestones
Advancing a Robust Pipeline with Multiple Value-Driving Milestones Ongoing Today 2026 2027 Trofinetide Ph 3 | Rett Syndrome Ph 3 | Readout Regulatory Submission Rett Syndrome | Japan Ph 2 | LBDP RADIANT Ph 2 | Readout Remlifanserin Ph 3s | ADP ADP + LBDP ACP-211 Ph 2 | MDD Ph 2 | Readout Major Depre
Slide 19: Q&A Session
Q&A Session 19 ] ®ACADIA
Acadia Pharmaceuticals — Technical Presentation (September 2026) on 6ix